Studies from Hokkaido University reveal new findings on cancer vaccines
2008 JAN 16 -- "Mice bearing established Lewis lung carcinoma (LLC) expressing model tumor antigen, ovalbumin (OVA) (LLC-OVA) marginally responded to local radiotherapy, but none of the mice was cured. In contrast, treatment of the tumor-bearing mice with intratumoral injection of tumor-specific T helper type 1 (Th1) cells and tumor antigen (OVA) after radiotherapy dramatically prolonged the survival days and induced complete cure of the mice at high frequency (80%)," scientists in Sapporo, Japan report. "Radiation therapy combined with Th1 cells or OVA alone showed no significant therapeutic activity against LLC-OVA. Such a strong therapeutic activity was not induced by intratumoral injection of Th1 cells plus OVA. Compared with other treatment, radiation therapy combined with Th1 cells and OVA was superior to induce the generation of OVA/H-2(b) tetramer (+) tumor-specific cytotoxic T lymphocyte (CTL) with a strong cytotoxicity against LLC-OVA in draining lymph node (DLN). Moreover, the combined therapy is demonstrated to inhibit the growth of tumor mass, which grew at contralateral side. These results indicated that radiotherapy combined with Th1 cell/vaccine therapy induced a systemic antitumor immunity," wrote H. Yokouchi and colleagues, Hokkaido University. The researchers concluded: "These findings suggested that combination therapy with radiotherapy and Th1 cell/vaccine therapy may become a practical strategy for cancer treatment." Yokouchi and colleagues published their study in Clinical & Experimental Metastasis (Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma. Clinical & Experimental Metastasis, 2007;24(7):533-540). For additional information, contact T. Nishimura, Hokkaido University, Institute Genetics Medical, Sect Diseases Control, Division Immunoregulat, Kita Ku, N15, W7, Sapporo, Hokkaido 0600815, Japan. The publisher's contact information for the journal Clinical & Experimental Metastasis is: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. Keywords: Japan, Sapporo, Biological Therapy, Biotechnology, Biotherapy, Cancer Vaccines, Cell Therapy, Experimental Metastasis, Immunotherapy, Infectious Disease, Lewis Lung Cancer, Lewis Lung Carcinoma, Lung Neoplasms, Medical Device, Oncology, Pulmonology, Radiation Therapy, Respiratory Infection, Treatment, Hokkaido University. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2008, Immunotherapy Weekly via NewsRx.com.
|
